Insight Molecular Diagnostics Inc. (IMDX)
NASDAQ: IMDX · Real-Time Price · USD
2.990
+0.320 (11.99%)
Sep 10, 2025, 12:27 PM - Market open

IMDX Stock Forecast

Stock Price Forecast

The 1 analyst with a 12-month price forecast for IMDX stock has a target of 4.25, which predicts a 42.14% increase from the current stock price of 2.99.

Price Target: $4.25 (+42.14%)
Analyst Consensus: Strong Buy
TargetLowAverageMedianHigh
Price$4.25$4.25$4.25$4.25
Change+42.14%+42.14%+42.14%+42.14%

Analyst Ratings

According to 1 stock analyst, the rating for IMDX is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

RatingSep '25
Strong Buy1
Buy0
Hold0
Sell0
Strong Sell0
Total1

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Needham
Needham
Strong Buy
Reiterates
$4.25
Strong BuyReiterates$4.25+42.14%Aug 18, 2025
More Analyst Ratings

Financial Forecast

Revenue This Year
3.23M
from 1.88M
Increased by 71.72%
Revenue Next Year
3.17M
from 3.23M
Decreased by -1.89%
EPS This Year
-0.99
from -4.66
EPS Next Year
-0.81
from -0.99
Fiscal YearFY 2020FY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2020Dec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
1.22M2.20M958.00K1.50M1.88M3.23M3.17M
Revenue Growth
-80.76%-56.42%56.89%25.15%71.72%-1.89%
EPS
-9.14-14.42-13.25-3.75-4.66-0.99-0.81
EPS Growth
-------
Forward PE
-------
No. Analysts
-----66
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue202520262027
High3.4M5.4M
Avg3.2M3.2M
Low3.0M1.1M

Revenue Growth

Revenue Growth202520262027
High
78.6%
65.8%
Avg
71.7%
-1.9%
Low
61.5%
-66.0%

EPS Forecast

EPS202520262027
High-0.96-0.74
Avg-0.99-0.81
Low-1.01-0.87

EPS Growth

EPS Growth202520262027
High--
Avg--
Low--
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.